Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based Living Cell Technologies has appointed Robert Caspari as the new CEO of the company.
Subscribe to our email newsletter
Dr Caspari was previously senior vice president commercial operations of Myogen; vice president and general manager for Biopharmaceuticals at Novo Nordisk Pharmaceuticals and more recently president and CEO of Aurogen.
Dr Paul Tan, Living Cell Technologies'(LCT’s) current CEO who is based in Auckland, New Zealand, will remain the CEO of LCT New Zealand Limited, LCT’s subsidiary in New Zealand, and assumes the role of COO for LCT.
The company has also started working with the Barbara Davis Center for Diabetes, Denver, Colorado, towards conducting a clinical trial there in 2009.
Dr Tan said: “I have enjoyed working with Mr Caspari on the board of LCT and look forward to accessing his experience on the management team to advance DiabeCell to the market.”